Roche Holding AG (OTCMKTS:RHHBY) Shares Sold by Beach Investment Counsel Inc. PA

Beach Investment Counsel Inc. PA reduced its stake in Roche Holding AG (OTCMKTS:RHHBY) by 17.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,560 shares of the company’s stock after selling 12,380 shares during the period. Beach Investment Counsel Inc. PA’s holdings in Roche were worth $2,008,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of RHHBY. Brooklyn Investment Group purchased a new position in shares of Roche during the third quarter worth about $40,000. AlphaMark Advisors LLC purchased a new stake in Roche in the 3rd quarter valued at approximately $149,000. IHT Wealth Management LLC purchased a new stake in Roche in the 3rd quarter valued at approximately $236,000. Verity Asset Management Inc. purchased a new stake in Roche in the 3rd quarter valued at approximately $253,000. Finally, Canopy Partners LLC boosted its holdings in Roche by 4.6% in the 3rd quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock valued at $310,000 after purchasing an additional 344 shares in the last quarter.

Roche Stock Up 0.2 %

Shares of Roche stock opened at $39.32 on Tuesday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26. Roche Holding AG has a 1 year low of $29.20 and a 1 year high of $42.43. The business has a 50 day moving average price of $36.22 and a 200 day moving average price of $38.28.

Analyst Upgrades and Downgrades

Separately, Sanford C. Bernstein raised Roche to a “strong-buy” rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Roche presently has a consensus rating of “Hold”.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.